Dr. Nadler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1026
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2005
- Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
- Harvard Medical SchoolClass of 2000
Certifications & Licensure
- TX State Medical License 2005 - 2025
- MA State Medical License 2002 - 2007
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Start of enrollment: 2010 Jun 01
- Optimal Tube Feeding Method in Head and Neck Cancer Patients Start of enrollment: 2015 Feb 01
- Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Publications & Presentations
PubMed
- 227 citationsMeasuring patient-centered communication in cancer care: a literature review and the development of a systematic approach.Lauren McCormack, Katherine Treiman, Douglas Rupert, Pamela Williams-Piehota, Eric Nadler
Social Science & Medicine. 2011-04-01 - 14 citationsReal-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.Eric Nadler, Anupama Vasudevan, Yunfei Wang, Sarika Ogale
Cancer Treatment and Research Communications. 2022-01-01 - 4 citationsReal-world relationship of early end points to survival end points in patients with resectable non-small-cell lung cancer.Eric Nadler, Anupama Vasudevan, Chuck Wentworth, Nicholas Robert, John R Penrod
Future Oncology. 2023-08-01
Press Mentions
- US Oncology Research, the US Oncology Network and Ontada Announce Clinical Data Showcased in Plenary and Oral Sessions at ASCO Annual MeetingJune 3rd, 2021
- OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerApril 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: